Study finds weight loss results drive continued Ozempic use despite nausea and other side effects, based on real world ...

By Tarun Sai Lomte Widely used weight-loss and diabetes drugs show clear benefits, but emerging evidence clarifies their side effects, rare risks, and what clinicians should monitor long term. Review: ...

An AI-designed obesity drug targeting the GIP receptor shows over 31% weight loss in preclinical tests, raising hopes for next-generation metabolic treatments beyond GLP-1 drugs.

The study found that the perceived effectiveness of Ozempic for weight loss is the primary driver of patient satisfaction and intent to continue treatment, even when experiencing side effects.

The recent withdrawal of Hims & Hers’ GLP-1 pill raises questions about the safety and effectiveness of compounded medications ...

Adults with obesity may now move directly from Wegovy 2.4mg to 7.2mg if they need greater weight loss ...

Novo Nordisk NVO announced that the European Commission (EC) has approved a new 7.2 mg once-weekly maintenance dose of Wegovy (semaglutide injection) for adults with obesity. This provides physicians ...

Victory Square Technologies Inc. (CSE: VST) (FSE: 6F6) (OTC Pink: VSQTF) (“Victory Square” or the “Company”) provides a ...

The AACE consensus statement emphasizes improvement of overall health in addition to weight reduction among adults with obesity and adiposity-based chronic disease.

People diagnosed with type 2 diabetes before age 40 face a higher lifetime risk of heart and kidney problems, so may benefit from adding another type of medicine called a GLP-1 receptor agonist (such ...

GLP-1 receptor agonists, originally developed for type 2 diabetes, are now witnessing soaring demand for weight management, with drugs like Ozempic gaining widespread popularity, particularly on ...

NICE recommends SGLT-2 inhibitors with metformin at diagnosis, citing major cardiovascular, renal, and mortality benefits.